Gilead’s Bixlenvo: FDA Approves the Smallest Once-Daily HIV Pill
The U.S. Food and Drug Administration has approved Bixlenvo, a groundbreaking once-daily HIV treatment from Gilead Sciences (NASDAQ: GILD). This approval, granted on August 28, 2026, signifies a significant advancement in HIV care. Bixlenvo combines bictegravir (75 mg) and lenacapavir (50 mg) into a single tablet, making it the smallest single-tablet HIV regimen currently available.
Designed specifically for adults with virologically suppressed HIV who are on complex multi-pill regimens and cannot use existing single-tablet options, Bixlenvo targets a patient population that accounts for an estimated 5% or more of individuals living with HIV in the United States. By targeting multiple stages of the HIV life cycle through two distinct mechanisms — an integrase strand transfer inhibitor and a capsid inhibitor — Bixlenvo provides a potent new alternative with no cross-resistance to other antiretrovirals.
The FDA’s approval was based on Phase 3 clinical trial data from the ARTISTRY-1 and ARTISTRY-2 trials. Bixlenvo demonstrated comparable efficacy and was generally well tolerated. The drug carries a list price of $4,595 for a 30-day supply, comparable to other daily single-tablet HIV treatments. Gilead CEO Daniel O’Day has hailed the approval as a potential first of many advances in the company’s expanding HIV pipeline.
Source: CNBC – August 28, 2026